We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

105 hedge funds and large institutions have $408M invested in KalVista Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 34 increasing their positions, 33 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 33

3.93% less ownership

Funds ownership: 99.59% → 95.67% (-3.9%)

5% less funds holding

Funds holding: 110 → 105 (-5)

20% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 20

28% less capital invested

Capital invested by funds: $567M → $408M (-$159M)

85% less call options, than puts

Call options by funds: $533K | Put options by funds: $3.54M

Holders
105
Holders Change
-5
Holders Change %
-4.55%
% of All Funds
1.84%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
34
Reduced
33
Closed
20
Calls
$533K
Puts
$3.54M
Net Calls
-$3.01M
Net Calls Change
-$417K

Top Buyers

Rank Fund Capital Flow
1
SCM
Suvretta Capital Management
New York
+$7.14M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$4.51M
3
FM
Frazier Management
Washington
+$3.18M
4
DCM
DAFNA Capital Management
California
+$2.61M
5
MIM
Monashee Investment Management
Massachusetts
+$2.53M

Top Sellers

Rank Fund Capital Flow
1
NIP
Nicholas Investment Partners
California
-$8.79M
2
State Street
State Street
Massachusetts
-$7.23M
3
EMFAT
Emerald Mutual Fund Advisers Trust
Pennsylvania
-$5.47M
4
VC
Vivo Capital
California
-$4.49M
5
Invesco
Invesco
Georgia
-$2.95M
Name Holding Trade Value Shares
Change 		Change in
Stake
EMFAT
26
Emerald Mutual Fund Advisers Trust
Pennsylvania
$2.38M -$5.47M -269,658 -66%
N
27
Nuveen
North Carolina
$2.35M -$4.8K -237 -0.2%
WP
28
Woodline Partners
California
$2.26M +$560K +27,645 +27%
MIM
29
Monashee Investment Management
Massachusetts
$2.18M +$2.53M +125,000 New
Two Sigma Investments
30
Two Sigma Investments
New York
$2.14M +$1.33M +65,765 +116%
Two Sigma Advisers
31
Two Sigma Advisers
New York
$2.1M +$2.07M +101,900 +550%
LCM
32
Laurion Capital Management
New York
$2.09M – – –
ACM
33
Altium Capital Management
New York
$1.95M – – –
TCM
34
Tekla Capital Management
Massachusetts
$1.75M – – –
IC
35
Ikarian Capital
Texas
$1.69M -$7.88K -389 -0.4%
Wells Fargo
36
Wells Fargo
California
$1.4M -$124K -6,111 -7%
NFGH
37
Nan Fung Group Holdings
Hong Kong
$1.37M – – –
Bank of New York Mellon
38
Bank of New York Mellon
New York
$1.28M -$252K -12,444 -15%
Goldman Sachs
39
Goldman Sachs
New York
$1.21M +$764K +37,685 +119%
Charles Schwab
40
Charles Schwab
California
$910K +$79.8K +3,937 +8%
Susquehanna International Group
41
Susquehanna International Group
Pennsylvania
$713K +$57.1K +2,819 +7%
Citadel Advisors
42
Citadel Advisors
Florida
$710K -$713K -35,186 -46%
BC
43
Birchview Capital
Vermont
$698K – – –
Rafferty Asset Management
44
Rafferty Asset Management
New York
$674K -$428K -21,124 -35%
Millennium Management
45
Millennium Management
New York
$641K +$744K +36,715 New
State of Wisconsin Investment Board
46
State of Wisconsin Investment Board
Wisconsin
$619K +$73K +3,600 +11%
CL
47
CSS LLC
Illinois
$611K +$294K +14,500 +71%
UBS Group
48
UBS Group
Switzerland
$580K +$586K +28,906 +669%
Massachusetts Financial Services
49
Massachusetts Financial Services
Massachusetts
$545K -$250K -12,332 -28%
JF
50
Jump Financial
Illinois
$537K +$624K +30,779 New
1
2
3 4 5

KALV Hedge Fund Activity: Q3 2021 in Review

105 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q3 2021, worth a combined $408M — down 28% from $567M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of KALV and 16 opened new positions — a net loss of 4 holders — while 33 trimmed existing stakes and 34 added.

The largest buyer was Suvretta Capital Management, adding an estimated $7.14M. The largest seller was Nicholas Investment Partners, cutting an estimated $8.79M.

  • 105 institutional investors held KalVista Pharmaceuticals (KALV) as of Q3 2021, down from 110 in Q2 2021.
  • Funds reported $408M of KalVista Pharmaceuticals stock for Q3 2021, down 28% quarter-over-quarter.
  • 16 funds opened new KalVista Pharmaceuticals positions in Q3 2021 and 20 closed out, a net change of -4 holders.
  • The largest KalVista Pharmaceuticals buyer in Q3 2021 was Suvretta Capital Management, an estimated $7.14M added.
  • The largest KalVista Pharmaceuticals seller in Q3 2021 was Nicholas Investment Partners, an estimated $8.79M sold.

Based on aggregated 13F filings for Q3 2021.